Monitor for subsequent pricing detail disclosures or government program expansions that could affect Attruby's revenue trajectory. Key catalysts to watch are the upcoming PDUFA dates for BBP-418 (Nov 2026) and encaleret (May 2027).
Price Chart
Executive Summary
BridgeBio announced a voluntary agreement with the U.S. government to lower drug costs and expand Medicaid access to its marketed medicine Attruby, with no future pricing mandates expected. The specific terms are confidential, but the deal excludes medicines approved exclusively for orphan indications and has no impact on the company's existing copay assistance program.
Key Facts
- Voluntary agreement with U.S. government to lower drug costs and expand Medicaid access to Attruby via the GENEROUS Model
- BridgeBio expects no future pricing mandates under this agreement
- Pricing commitments exclude medicines approved exclusively for orphan indications
- Attruby will continue to be offered via Medicare Part D without future pricing mandates
- The ForgingBridges copay assistance program is unaffected
- Specific terms of the agreement remain confidential
- CEO Neil Kumar joined President Trump at the White House to discuss the agreement
- BridgeBio has three additional medicines under FDA review: BBP-418 (PDUFA Nov 27, 2026), encaleret (PDUFA May 7, 2027), and infigratinib for achondroplasia
Financial Impact
No specific dollar amounts disclosed — agreement terms are confidential. Impact on pricing and revenue for Attruby and future medicines is unquantifiable from this filing.
Risk Factors
- Implementation of the agreement may differ from current expectations
- Future changes in federal laws or pricing programs could override the agreement's protections
- Confidential terms may have undisclosed revenue or pricing constraints
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-035055 |
| Document: ef20081330_ex99-1.htm | 0001140361-26-035055 |
| Document: 0001140361-26-035055-index-headers.html | 0001140361-26-035055 |
| Document: 0001140361-26-035055-index.html | 0001140361-26-035055 |
| Document: 0001140361-26-035055.txt | 0001140361-26-035055 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $76.59 $65.97 | ▼ −13.87% | ▼ −13.68% | $67.47 (−11.90%) |
Aug 26, 2026 5w ago | Press Release | $79.37 $66.28 | ▼ −16.49% | ▼ −16.72% | $67.47 (−14.99%) |
Aug 22, 2026 5w ago | Institutional Cluster | $81.07 $69.23 | ▼ −14.60% | ▼ −15.92% | $67.47 (−16.77%) |
Aug 17, 2026 6w ago | 8-K | $79.89 $72.38 | ▼ −9.40% | ▼ −7.87% | $67.47 (−15.54%) |
Aug 13, 2026 7w ago | Press Release | $79.86 $72.38 | ▲ +9.37% | ▲ +7.38% | $67.47 (+15.51%) |
Aug 10, 2026 7w ago | 8-K | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Aug 10, 2026 7w ago | Press Release | $84.67 $76.08 | ▼ −10.15% | ▼ −9.09% | $67.47 (−20.31%) |
Jul 13, 2026 11w ago | Insider Cluster | $83.08 $84.67 | ▲ +1.91% | ▼ −1.27% | $67.47 (−18.78%) |
Jun 28, 2026 13w ago | Press Release | $72.01 $84.02 | ▲ +16.68% | ▲ +16.96% | $67.47 (−6.30%) |
Jun 24, 2026 14w ago | 144 | $69.69 $82.93 | ▲ +19.00% | ▲ +18.47% | $67.47 (−3.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access